annb0t
Top 20
SYDNEY, April 29, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of a poster presentation at the upcoming Annual Meeting of the American Society for Clinical Oncology (ASCO). Kazia Therapeutics Limited Logo (PRNewsfoto/Kazia Therapeutics Limited)
The ASCO Annual Meeting will take place virt...
>>> Read more: KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ASCO
The ASCO Annual Meeting will take place virt...
>>> Read more: KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ASCO
